Stockscreener 앱 받기
27.08
2.59%
-0.56
전일 마감가:
$27.64
열려 있는:
$27.28
하루 거래량:
26,632
Relative Volume:
0.22
시가총액:
$408.87M
수익:
$138.20M
순이익/손실:
$5.52M
주가수익비율:
71.26
EPS:
0.38
순현금흐름:
$9.86M
1주 성능:
-13.42%
1개월 성능:
-8.17%
6개월 성능:
-28.51%
1년 성능:
-17.13%
1일 변동 폭
$26.94
$28.10
1주일 범위
$26.00
$31.22
52주 변동 폭
$26.00
$42.44
Surmodics Inc Stock (SRDX) Company Profile
명칭
Surmodics Inc
전화
(952) 500-7000
주소
9924 W 74TH ST, EDEN PRAIRIE, MN
SRDX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SRDX
Surmodics Inc
|
27.05 | 408.87M | 138.20M | 5.52M | 9.86M | 0.38 |
|
ABT
Abbott Laboratories
|
132.26 | 224.65B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
104.55 | 151.13B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
382.49 | 139.34B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
83.41 | 108.80B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
75.32 | 44.25B | 5.54B | 4.18B | 259.90M | 7.00 |
Surmodics Inc Stock (SRDX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-07 | 업그레이드 | Lake Street | Hold → Buy |
| 2023-06-13 | 업그레이드 | Needham | Hold → Buy |
| 2023-02-13 | 다운그레이드 | Needham | Buy → Hold |
| 2020-07-23 | 업그레이드 | Needham | Hold → Buy |
| 2019-12-11 | 다운그레이드 | Needham | Buy → Hold |
| 2019-11-01 | 다운그레이드 | Lake Street | Buy → Hold |
| 2019-08-01 | 재확인 | Needham | Buy |
| 2019-05-02 | 재확인 | Lake Street | Buy |
| 2019-05-02 | 재확인 | Needham | Buy |
| 2019-02-21 | 재확인 | Needham | Buy |
| 2018-05-16 | 재확인 | Needham | Buy |
| 2018-03-01 | 업그레이드 | Sidoti | Neutral → Buy |
| 2018-02-28 | 재확인 | Lake Street | Buy |
| 2018-02-28 | 개시 | Needham | Buy |
| 2017-07-14 | 개시 | Lake Street | Buy |
| 2016-11-21 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
| 2016-10-06 | 다운그레이드 | Sidoti | Buy → Neutral |
| 2016-05-03 | 재확인 | Barrington Research | Outperform |
| 2015-08-06 | 재확인 | Barrington Research | Outperform |
| 2015-03-27 | 개시 | Dougherty & Company | Buy |
| 2014-02-25 | 개시 | Laidlaw | Buy |
| 2013-08-01 | 업그레이드 | Feltl & Co. | Buy → Strong Buy |
| 2012-11-12 | 재확인 | Barrington Research | Outperform |
모두보기
Surmodics Inc 주식(SRDX)의 최신 뉴스
Are Options Traders Betting on a Big Move in Surmodics Stock? - Nasdaq
SRDX Stock Down Following Q2 Earnings Miss, Gross Margin Contracts - Yahoo Finance
Surmodics Reports Q2 2025 Results Amid Acquisition Challenges - TipRanks
SurModics: Fiscal Q2 Earnings Snapshot - MySA
SurModics (SRDX) Reports Q2 Earnings: What Key Metrics Have to Say - Yahoo Finance
SurModics stock touches 52-week low at $26.21 amid market shifts - Investing.com
Surmodics (SRDX) Projects Declining Revenue for Fiscal 2025 | SR - GuruFocus
Surmodics Reports Second Quarter of Fiscal Year 2025 Financial Results; Introduces Fiscal Year 2025 Financial Guidance - BioSpace
Surmodics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
SurModics (SRDX) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Surmodics (SRDX) Reports Lower Than Expected Q2 Revenue Amid Ant - GuruFocus
SURMODICS INC SEC 10-Q Report - TradingView
Surmodics Reports Second Quarter of Fiscal Year 2025 Financial R - GuruFocus
Surmodics Reports Second Quarter of Fiscal Year 2025 Financial Results; Introduces Fiscal Year 2025 Financial Guidance | SRDX Stock News - GuruFocus
Surmodics Reports Second Quarter Fiscal 2025 Financial Results - TradingView
A Look at Surmodics's Upcoming Earnings Report - Nasdaq
How To Trade (SRDX) - news.stocktradersdaily.com
Surmodics to Report Second Quarter of Fiscal 2025 Financial Results on April 30 - 01net
Surmodics to Report Second Quarter of Fiscal 2025 Financial Resu - GuruFocus
FTC Expands Lawsuit Against GTCR Over Surmodics Acquisition - MSN
Surmodics' SurVeil DCB Matches IN.PACT Admiral In Efficacy With Lower Drug Dose In Global Trial - Nasdaq
Surmodics (SRDX) Publishes Promising Clinical Trial Results for SurVeil DCB | SRDX Stock News - GuruFocus
Surmodics Announces Publication of TRANSCEND Trial, Highlighting - GuruFocus
Surmodics Announces Publication of TRANSCEND Trial, Highlighting Drug-Delivery Technology of its SurVeil™ Drug-Coated Balloon - Business Wire
Geode Capital Management LLC Sells 2,639 Shares of Surmodics, Inc. (NASDAQ:SRDX) - Defense World
Illinois, Minnesota join FTC challenge against $627M Surmodics buyout - MedTech Dive
Minnesota AG Ellison joins federal lawsuit to stop merger of companies that make medical device coatings - KIMT
Illinois joins FTC suit to block GTCR’s takeover of Surmodics - Crain's Chicago Business
AG Ellison Joins Suit to Block Surmodics Acquisition - Twin Cities Business
Corebridge Financial Inc. Lowers Stock Position in Surmodics, Inc. (NASDAQ:SRDX) - Defense World
(SRDX) Long Term Investment Analysis - news.stocktradersdaily.com
Surmodics Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm - ACCESS Newswire
SRDX Stock Dips Despite the Launch of Pounce XL Thrombectomy System - Yahoo Finance
Surmodics launches Pounce XL for peripheral artery clot removal By Investing.com - Investing.com South Africa
Surmodics launches Pounce XL thrombectomy system - Yahoo Finance
Surmodics launches Pounce XL for peripheral artery clot removal - Investing.com Australia
Revolutionary Blood Clot Treatment: Pounce XL Shows 80% Success Rate in Just 20 Minutes - Stock Titan
Surmodics Announces Commercial Release of Pounce™ XL Thrombectomy System, Enabling Rapid Non-Surgical Clot Removal in Iliac and Femoral Arteries - Yahoo Finance
Gardner Lewis Asset Management L P Raises Position in Surmodics, Inc. (NASDAQ:SRDX) - MarketBeat
Learn to Evaluate (SRDX) using the Charts - news.stocktradersdaily.com
PE Firm Hits Back Against Medical Device Coating Challenge - Law360
FTC Challenges Medical Device Coatings Deal - Medical Product Outsourcing
Zacks Research Decreases Earnings Estimates for Surmodics - Defense World
Bank of New York Mellon Corp Sells 2,966 Shares of Surmodics, Inc. (NASDAQ:SRDX) - Defense World
Here's Why You Should Retain Surmodics Stock in Your Portfolio Now - Zacks Investment Research
FTC’s First Merger Challenge Under New Leadership Signals Return to Traditional Antitrust Theories in Private Equity Deals - JD Supra
GTCR / Surmodics: Four Key Takeaways for M&A Antitrust from the First FTC Merger Challenge Under Trump - JD Supra
FTC sues to block GTCR’s ‘unlawful acquisition’ of Surmodics - Yahoo Finance
Medical Coating Market Projected To Witness Substantial Growth, 2025-2032: Freudenberg Medical Europe GmbH, - EIN News
FTC Fights to Block Merger Threatening Healthcare Innovation and Patient-Critical Devices - MyChesCo
Surmodics (NASDAQ:SRDX) Stock Rating Upgraded by Lake Street Capital - Defense World
Surmodics Inc (SRDX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Surmodics Inc 주식 (SRDX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| DANTZKER DAVID | Director |
Feb 13 '25 |
Option Exercise |
27.30 |
5,275 |
144,008 |
44,399 |
| BEDOYA JOSE H | Director |
Feb 14 '25 |
Option Exercise |
27.30 |
5,275 |
144,008 |
34,232 |
| KNIGHT SUSAN E | Director |
Jan 24 '25 |
Option Exercise |
27.30 |
7,358 |
200,873 |
42,506 |
| Arens Timothy J. | Chief Financial Officer |
Nov 26 '24 |
Sale |
39.44 |
7,009 |
276,453 |
70,350 |
10.11%
0.14%
자본화:
|
볼륨(24시간):